InSitu Biologics, Inc.
Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.
Raised
$15M
Investors
27
Min Invest
$1,850
Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.
What this filing shows
·Every sentence is a value as filed on SEC Form D
InSitu Biologics, Inc. is a Delaware corporation that first filed a Form D on July 24, 2019 and most recently amended it on November 10, 2026 in the Biotechnology industry group. The offering claims Rule 506(b) and covers debt. InSitu Biologics, Inc. reported $15,037,850 sold from 27 investors of a $19,837,423 total offering as of the Form D filed November 10, 2026. The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The minimum investment accepted from an outside investor is $1,850. The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly. Sales commissions are reported as $0 and finders' fees as $0. Form D allows these to be estimates. The issuer's address of record is 3510 Hopkins Place N., Building 4, Oakdale, MN 55128.
Critical Disclosures
What the filings and the regulators have said about this entity that a reader should know first. Each line links to its source. The history, the same event across other issuers, and alerts are in the terminal.
Change in control · Form 1-U · September 3, 2019
Annual financial statements for the period ended December 31, 2019, audited
Going concern: substantial doubt raised in the statements or the auditor's report. The figures are in the terminal.
EDGAR Filing Data
Form D — Primary Source
View on SEC.govFilings on Record
Every filing AltStreet's ledger holds for this CIK, newest first (15 of 34). Each opens the SEC archive folder.
In the Terminal
Filing events
34
latest Nov 10, 2026
Critical / warning
0 / 1
7 watch · 26 info
Statements extracted
3
through Dec 31, 2019
NAV prints
0
none on file
Offering chains
7
pre_sale, lapsed, raising, exited
Latest event Sold increase · Nov 10, 2026
SEC.govInvestor
- The dated record: 31 facts with source, effective date and capture date, viewable as AltStreet knew them on any past day
- 3 extracted financial statements: assets, liabilities, equity, revenue, net income, cash, latest for the period ended 2019-12-31
- 34 filing events with values and deltas, latest 2026-11-10, and alerts on the next one
- 7 offering timelines: velocity, share raised, first-sale lag, stalled flags
Pro
- This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
- The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV
Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…
Auditor of Record
As named on this issuer's SEC filings · Audited · see all issuers this firm audits
Related Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
Item 3 changed on the Form D filed 2026-11-10: 1 related person added and 1 removed against the filing of 2026-10-14; 6 now listed. The names are in the Terminal feed.
Daniel Halpern
Executive Officer, Director · Oakdale, MN
William Taylor
Executive Officer · Oakdale, MN
Sandi Klemann
Executive Officer · Oakdale, MN
Robert Wilson
Director · Oakdale, MN
Greg Van Guilder
Director · Oakdale, MN
Ivan Shaw
Director · Oakdale, MN
Questions About InSitu Biologics, Inc.
Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.
What is InSitu Biologics, Inc.?
InSitu Biologics, Inc. is a Delaware corporation that filed a Form D with the SEC on November 10, 2026 in the Biotechnology industry group. The filing claims Rule 506(b) for an offering of debt.
Is InSitu Biologics, Inc. legit?
AltStreet does not rate legitimacy; it reports the public record. InSitu Biologics, Inc. filed a Form D with the SEC on November 10, 2026 claiming Rule 506(b). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $15,037,850 sold to 27 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.
Is InSitu Biologics, Inc. registered with or approved by the SEC?
No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that InSitu Biologics, Inc. claimed Rule 506(b) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.
How much has InSitu Biologics, Inc. raised?
InSitu Biologics, Inc. reported $15,037,850 sold from 27 investors of a $19,837,423 total offering as of the Form D filed November 10, 2026.
Who can invest in InSitu Biologics, Inc.?
The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The minimum investment accepted from an outside investor is $1,850.
What is the minimum investment in InSitu Biologics, Inc.?
The Form D lists $1,850 as the minimum investment accepted from any outside investor as of November 10, 2026. Issuers can waive their own minimums, and the figure does not include fees.
Who is selling InSitu Biologics, Inc. and how are they paid?
The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly. Sales commissions are reported as $0 and finders' fees as $0. Form D allows these to be estimates.
Who is behind InSitu Biologics, Inc.?
The Form D lists 6 related persons: Daniel Halpern, executive officer, director; William Taylor, executive officer; Sandi Klemann, executive officer; Robert Wilson, director; Greg Van Guilder, director; Ivan Shaw, director. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.
Where is InSitu Biologics, Inc. located?
The issuer's address on its SEC filings is 3510 Hopkins Place N., Building 4, Oakdale, MN 55128. Its phone number of record is 651-337-4799. It is organized under the laws of Delaware.
How long is the InSitu Biologics, Inc. offering open?
The issuer indicated that the offering is intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open; 2 amendments are on record for this CIK.
What is InSitu Biologics, Inc.'s revenue?
The issuer declined to disclose its revenue range on the Form D, which the form permits.

Is this your company or fund?
Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.
Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.
